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Abstract
Background: ANGPTL8 (betatrophin) has been recently identified as a regulator of lipid metabolism through its
interaction with ANGPTL3. A sequence variant in ANGPTL8 has been shown to associate with lower level of Low
Density Lipoprotein (LDL) and High Density Lipoprotein (HDL). The objective of this study is to identify sequence
variants in ANGPTL8 gene in Arabs and investigate their association with ANGPTL8 plasma level and clinical
parameters.
Methods: A cross sectional study was designed to examine the level of ANGPTL8 in 283 non-diabetic Arabs, and
to identify its sequence variants using Sanger sequencing and their association with various clinical parameters.
Results: Using Sanger sequencing, we sequenced the full ANGPTL8 gene in 283 Arabs identifying two single
nucleotide polymorphisms (SNPs) Rs.892066 and Rs.2278426 in the coding region. Our data shows for the first time
that Arabs with the heterozygote form of (c.194C > T Rs.2278426) had higher level of Fasting Blood Glucose (FBG)
compared to the CC homozygotes. LDL and HDL level in these subjects did not show significant difference between
the two subgroups. Circulation level of ANGPTL8 did not vary between the two forms. No significant changes were
observed between the various forms of Rs.892066 variant and FBG, LDL or HDL.
Conclusion: Our data shows for the first time that heterozygote form of ANGPTL8 Rs.2278426 variant was associated
with higher FBG level in Arabs highlighting the importance of these variants in controlling the function of betatrophin.
Keywords: ANGPTL8, LDL, HDL, Lipid metabolism, Glucose metabolism, Sanger sequencing, Single nucleotide
polymorphism
Background
Diabetes prevalence is reaching epidemic proportion
with increasingly more people affected by either Type 1
diabetes (T1D) that is caused by insulin deficiency or
Type 2 Diabetes (T2D) that is caused by insulin resistance
[1–6]. Regeneration of beta cells in both diseases has been
regarded as an ultimate goal that could improve or replace
diabetes therapies for both diseases [7]. Accumulated
research data has shown that beta cells have the cap-
acity to compensate for increased insulin demand under
physiological conditions such as pregnancy as well as
insulin resistance in pathological conditions such as
obesity [8]. Factors such as the gut derived hormones
glucagon like peptide 1 (GLP1) and glucose-dependent
insulin-tropic polypeptide has been shown to increase
insulin secretion and to increase beta cell proliferation [9].
ANGPTL8 also called betatrophin has been recently
shown to affect beta-cell proliferation and suggested as a
possible target for beta-cell regeneration [9, 10]. Earlier
studies gave betatrophin the name ANGPTL8 protein
due to its sequence similarity to members of the angio-
poietin like protein (ANGPTL) family [11, 12]. It has
been shown to interact with ANGPTL3 and regulate
triglyceride (TG) and fatty acid metabolism. Ren et al.
showed that ANGPTL8 was induced during adipogenesis
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of primary mouse and human adipocytes as well as
3T3 L1 adipogenesis [13]. Reduction in betatrophin was
also associated with reduced adipogenesis which was dis-
tinguished by reduced TG [13]. Similarly, mice lacking
betatrophin had a similar TG level in the fasting state
compared to wild type and a rather lower TG level after
feeding [13]. They also failed to properly store fatty acids
in adipose tissue and showed a slower weight gain com-
pared to wild type littermates [13]. Nonetheless, they did
not show any changes in glucose homeostasis in mice fed
with chow or high fat diet. In humans, it has been shown
that betatrophin was increased in T1D [14] and T2D
subjects [15–20].
A coding variant in ANGPTL8 (Rs2278426, c.194C > T)
responsible for an amino acid change in the encoded pro-
tein (R59W) has been shown to be associated with lower
plasma LDL and HDL in African American and Hispanic
in the Dallas Heart Study [12]. Ethnic variation has been
observed in the minor allele frequency (MAF) of this vari-
ant and its association with LDL and HDL, as Europeans
had lower MAF and did not show any association between
R59W and levels of LDL and HDL in the Dallas Heart
Study [12]. To study the effect of ANGPTL8 sequence
variants in Arabs, we used Sanger sequencing to iden-
tify novel ANGPTL8 variants. We used Arab subjects
from our sample cohort to identify sequence variations
in ANGPTL8 and to study their association with the
level of circulating ANGPTL8 and other metabolic risk
factors particularly FBG, TG, LDL and HDL.
Research design and methods
Study participants
This is a cross sectional survey undertaken on 283 adult
(>18 years old) Arabs living in Kuwait. As previously
described, subjects included in this study were selected
randomly from a large cohort that has been randomly
collected from multi-ethnic subjects living in Kuwait
[17, 21–24]. Samples were collected from the six gover-
norates of the state of Kuwait, where random sample
was collected from each stratum with proportional allo-
cations. The study conformed to the principles outlined
in the Declaration of Helsinki and was approved by the
Scientific Advisory Board and Ethical Review Committee
at Dasman Diabetes Institute (DDI). An informed writ-
ten consent was obtained from all the participants before
their enrolment in the study. Subjects with Diabetes or
CVD and taking any medications were excluded from
the study.
Anthropometric and physical measurements
Physical and anthropometric measurements included body
weight, height, waist circumference (WC) and Blood Pres-
sure (BP). As previously described [17, 21, 23, 24], height
and weight were measured, with participants wearing light
indoor clothing and barefooted, using calibrated portable
electronic weighing scales and portable inflexible height
measuring bars. WC was measured using constant tension
tape at the end of a normal exhalation, with arms relaxed
at the sides, at the highest point of the iliac crest and at
the mid-axillary line. BP was measured with Omron
HEM-907XL Digital sphygmomanometer. The average
of 3 BP readings, with 5 to 10 min rest between each,
was obtained. BMI was calculated using the standard
BMI formula: body weight (in kilograms) divided by
height (in meters squared).
Laboratory measurements
Blood samples were obtained after fasting overnight for
at least 10 h and analyzed for FBG, HbA1c, fasting insulin,
and lipid profiles that included TG, TC, LDL and HDL.
Glucose and lipid profiles were measured on the Siemens
Dimension RXL chemistry analyzer (Diamond Diagnos-
tics, Holliston, MA). HbA1c was determined using the
VariantTM device (BioRad, Hercules, CA). All laboratory
tests were performed by certified technicians at the
clinical laboratories of DDI using the Ministry of Health
approved methods and quality standards.
ELISA betatrophin level
To measure metabolic markers, blood was drawn into
EDTA tubes. Plasma was obtained after centrifugation,
aliquoted and then stored at −80 °C. Betatrophin con-
centration was determined using ELISA (Wuhan EIAAB
Science co) as described previously [14, 15]. A range of
betatrophin concentrations were used to spike in plasma
at different dilution factors. The assay showed linearity
at dilutions ranging from 1:10–1:40. Recovery of the
known proteins ranged from 85 to 109 %. No significant
cross reactivity with other proteins has been observed.
Intra-assay coefficients of variation were 1.2 to 3.8 %,
while the inter-assay coefficients of variation were 6.8 to
10.2 %.
DNA sequencing
Genomic DNA was extracted from whole blood which
was withdrawn from different study participants as out-
lined above. DNA was extracted from the blood using
Gentra Puregene kit (Qiagen) as per the manufacturer’s
protocol. Coding exons and exon-intron boundaries
(splice sites) of the TD26 gene were amplified using
genomic DNA (25 ng per reaction) via polymerase chain
reaction (PCR), in 25 μl amplification mix containing
the corresponding M13 sequence-tagged primers pair
and GoTaq® Green Master mix (Promega). Amplified
PCR products were purified using ExoSAP-IT (Affyme-
trix) for the subsequent Sanger’s sequencing, using Big
Dye terminator cycle sequencing kit (Applied Biosys-
tems). Bi-directional sequencing reactions were carried
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out on each purified product using the generic M13
primer sequence tags. The sequencing products were
then cleaned to remove unincorporated dye using DyeEx
2.0 Spin Kit (Qiagen), and finally denatured and loaded
on the ABI Prism 3730xl Genetic Analyzer (Applied Bio-
systems) for sequencing. The resulting sequence contigs
were analyzed and aligned against a reference sequence
using the Chromas Pro software to detect the sequence
variations. Two SNPs were identified from the analysis
(c.27C > G, L9L and c.194C > T, A59W) Fig. 1a, b & c.
Statistical analysis
We compared the baseline characteristics of the partici-
pants using analysis of variance tests (ANOVA) for
continuous variables. Categorical variables were ana-
lysed using the chi-square test. Mean betatrophin and
CVDs risk factors (LDL, HDL, and FBG) values were
estimated within each group of homozygous referent
(HR), heterozygous (HET), and homozygous variant
(HV) genotypes for each SNP. The betatrophin, LDL,
HDL, and FBG levels were adjusted by age, gender and
BMI using analysis of covariance (ANCOVA) approach.
Data is reported as mean ± standard deviation (SD) and
range, unless stated otherwise. A P-value, 0.05 was consid-
ered to be statistically significant. All analyses were per-
formed using SAS (version 9.4; SAS Institute, Cary, NC).
Genotype frequencies were determined according to the
Hardy-Weinberg equilibrium (HWE).
Results
Overall population characteristics and phenotype
distribution
Our population was comprised of a total of 283 non-
diabetic Arab subjects. Characteristics of the study
Fig. 1 ANGPTL8 gene and protein sequence. a A diagram showing the sequence location of various introns and exons of the ANGPTL8 gene
and the location of the sequence variants. b Sanger sequencing raw data showing the location of the heterozygote and the Homozygote genotype
nucleic acid bases in respect to the ANGPTL8 reference sequence. c A diagram showing the location of the R59W variant in respect to ANGPTL8
protein domains
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population are outlined in Table 1. Using Sanger Sequen-
cing method, two sequence variants were identified in
ANGPTL8 gene (Rs.892066 and Rs.2278426) Fig. 1. A total
of 283 Arab samples were sequenced, 188 (66.4 %) had
homozygote form of Rs.892066 (C/C), while 85 (30.1 %)
were heterozygotes (C/G) and only 10 (3.5 %) were homo-
zygote (G/G) (Table 2). For the second sequence variant
identified in ANGPTL8 Rs.2278426, a total of 248 (87.6 %)
participants had homozygote form of this variant (C/C),
while 35 (12.4 %) were heterozygotes (C/T), none of the
sequenced samples had the homozygote (T/T) genotype
(Table 3).
Population characteristics stratified according to
ANGPTL8 variants
In order to identify differences between the two different
genotypes for Rs.2278426 SNP, population was stratified
according to sequence variant (wild type C/C or hetero-
zygote C/T). Subjects with heterozygote form C/T had
higher FBG level of (5.19 ± 0.10 mmol/L) than wild type
C/C form (4.97 ± 0.04 mmol/L) (p-value = 0.00372) Fig. 2.
No significant difference was observed in age, BMI and
TC. Age for wild type was 41.53 ± 0.68 year and 40.43 ±
1.82 year for heterozygote (p-value =0.5728). BMI was
31.37 ± 0.44 for wild type and 32.29 ± 1.16 for heterozy-
gote (p-value = 0.4622). No statistically significant dif-
ference was also observed in TC (wild type = 5.21 ±
0.07 mmol/L vs. 5.04 ± 0.18 mmol/L for heterozygote
(p-value = 0.3930)).
Lipid profile in different variants
LDL and HDL levels showed a trend of decrease in the
heterozygote form of Rs.2278426, which was not statisti-
cally significant. LDL level in the wild type form of
ANGPTL8 was 3.43 ± 0.06 mmol/L compared to 3.23 ±
0.17 mmol/L (p-value = 0.1085) in the heterozygote form
as seen in Fig. 3a. Similarly HDL also showed a similar trend
of being lower in the heterozygote 1.05 ± 0.06 mmol/L vs.
1.16 ± 0.02 mmol/L in the wild type (p-value = 0.1121)
Fig. 3b. Finally, circulation level of ANGPTL8 did not
show significant difference between both forms, wild
type was 812.5 ng/mL (215.7–9305.6) vs. 786.3 ng/mL
(192.9–1899.2) for the heterozygote (p-value = 0.5677).
No significant difference in FBG, LDL, HDL, TG or
betatrophin level was observed between the different
variants of Rs.892066.
Discussion
ANGPTL8 is a recently identified protein that has been
shown to play a role in lipid metabolism. Sequence variants
of ANGPTL8 gene has been associated with decreased
LDL and HDL level in African Americans and Hispanic
[12]. This study was aimed at identifying genetic difference
in the sequence of ANGPTL8 gene in Arabs and exploring
their association with metabolic risk factors. Our data
showed for the first time that Arab subjects with the C/T
heterozygote genotype of Rs.2278426 variant had higher
FBG level compared to the wild type. No difference in
FBG was observed between other genetic variants. On the
other hand, subjects with the C/T genotype of Rs.2278426
did not show significant difference in their LDL and HDL
level compared to homozygote genotype. The trend
however, was not statistically significant. Circulation
level of ANGPTL8 was not affected by the various
genotypes for both SNPs.
ANGPTL8 is a recently characterized protein that is
mainly produced in the liver and adipose tissue. It has
been established as a regulator of lipid metabolism. A
sequence variant in betatrophin (Rs2278426, c.194C > T;
R59W) has been shown to be associated with lower
plasma LDL-C and HDL-C [12]. Ethnic variation has been
associated with variable minor allele frequency (MAF)
rates for this variant in respect to LDL-C and HDL-C
plasma levels [12]. Hispanic had the highest 59 W MAF of
26 %, followed by African American (18 %) and the least
was reported in European Americans (5 %) [12]. This
variant was associated with lower LDL-C and HDL-C
in African Americans and Hispanic but not European
Table 1 Clinical and biochemical profile of the study
population
Variables Participants (n = 283)
Age (years) 41.39 ± 10.77
Male (%) 156 (55.8 %)
BMI (kg/m2) 31.49 ± 6.84
Waist/hip 0.90 ± 0.14
FBG (mmol/l) 5.00 ± 0.57
HBA1C (%) 5.37 ± 0.66
Insulin (mU/L) 9.02 ± 5.32
HOMAIR 2.04 ± 1.39
TRIG (mmol/l) 1.51 ± 0.80
HDL (mmol/l) 1.15 ± 0.37
LDL (mmol/l) 3.40 ± 1.00
Betatrophin ng/mL 808.82 (192.9–9305.56)
Rs.892066 (%)
CC 188 (66.4 %)
CG 85 (30 %)
GG 10 (0.3.6 %)
Rs2278426 (%)
(R59W)
CC 248 (87.6 %)
CT 35 (12.4 %)
Results are reported as Mean ± SD except for non-normally distributed betatro-
phin that are presented as Median (range)
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Americans in the Dallas Heart Study [12]. No association
was observed with TG level in any of the ethnicities [12].
In this study and in line with earlier reports, we showed a
trend towards lower LDL and HDL level in the R59W
variant, however, it was not statistically significant F.
In this study we showed that Arabs with the CT hetero-
zygote form of Rs.2278426 had a higher level of FBG
compared to those with CC homozygote form. This data
suggest that ANGPTL8 plays a role in glucose metabolism
in Arabs. ANGPTL8 or betatrophin role in beta-cell pro-
liferation has been recently questioned. Gusarova et al.
has suggested that betatrophin was not responsible for
any beta-cell proliferation and mice lacking ANGPTL8
had normal glucose metabolism under insulin resistance
conditions [12]. Similar data was observed by Quagliarini
et al. in Hispanic participants of the Dallas Heart Study
(DHS) study but not in African Americans or Europeans
[12]. In the DHS cohort, Hispanic subjects with the
homozygote form had significantly higher FBG (100 ±
9 mg/dL) compared to homozygote (CC) genotype that
had (93 ± 11 mg/dL) [12]. However, this was only observed
in a very small number of participants which was ignored
in their discussion. Even though the exact mechanism for
Table 2 Characteristics of the ANGPTL8 SNP Rs.892066 variants according to their genotype
Variable SNP Rs.892066 (N = 283)
CC (n = 188) CG (n = 85) GG (n = 10) p-value
Age 41.43 ± 0.79 41.24 ± 1.17 41.90 ± 3.42 0.9803
Gender
Male 90 (31.8 %) 39 (13.8 %) 4 (1.4 %) 0.8621
Female 98 (34.6 %) 46 (16.3 %) 6 (2.1 %)
BMI (kg/m2) 31.59 ± 0.49 30.92 ± 0.74 34.30 ± 2.16 0.3139
FBG (mmol/l) 4.98 ± 0.04 5.03 ± 0.06 5.03 ± 0.18 0.8391
HBA1C % 5.37 ± 0.05 5.35 ± 0.07 5.44 ± 0.21 0.9277
Insulin (mU/L) 9.71 ± .48 8.73 ± .72 11.56 ± 2.10 0.3196
HOMAIR 2.23 ± .13 2.0 ± .19 2.70 ± .55 0.3981
LDL (mmol/l) 3.41 ± 0.07 3.39 ± 0.11 3.50 ± 0.32 0.9752
HDL (mmol/l) 1.17 ± 0.03 1.11 ± 0.04 1.13 ± 0.12 0.4563
TCH (mmol/l) 5.19 ± 0.08 5.18 ± 0.12 5.31 ± 0.35 0.9382
TG (mmol/l) 1.47 ± 0.06 1.54 ± 0.09 1.94 ± 0.25 0.1715
Betatrophin ng/mL 791.7 (215.7–7264.3) 828.1 (192.9–9305.6) 815.0 (621.4–1310.8) 0.8600
Results are reported as Mean ± SE except for non-normally distributed betatrophin that are presented as Median (range)
Table 3 Characteristics of the ANGPTL8 SNP Rs.2278426 variants
according to their genotype
Variable Rs.2278426 (N = 283)
CC (n = 248) CT (n = 35) p-value
Age (Year) 41.53 ± 0.68 40.43 ± 1.82 0.5728
Gender
Male 121 (42.8) 12 (4.2) 0.1075
Female 127 (44.9) 23 (8.1)
BMI (kg/m2) 31.37 ± 0.44 32.29 ± 1.16 0.4622
FBG (mmol/l) 4.97 ± 0.04 5.19 ± 0.10 0.0372
HBA1C % 5.38 ± 0.04 5.30 ± 0.11 0.4751
Insulin (mU/L) 9.34 ± .42 10.49 ± 1.12 0.3353
HOMAIR 2.12 ± .11 2.49 ± .29 0.2381
LDL (mmol/l) 3.43 ± 0.06 3.23 ± 0.17 0.285
HDL (mmol/l) 1.16 ± 0.02 1.05 ± 0.06 0.1121
TCH (mmol/l) 5.21 ± 0.07 5.04 ± 0.18 0.3930
TG (mmol/l) 1.48 ± 0.05 1.71 ± 0.14 0.1030
Betatrophin ng/mL 812.5 (215.7–9305.6) 786.3 (192.9–1899.2) 0.5677
Results are reported as Mean ± SE except for non-normally distributed
betatrophin that are presented as Median (range)
Fig. 2 Fasting Blood Glucose level in the homozygote genotype
and heterozygote form of the Rs.2278426 SNP. Heterozygote forms
of the SNP showing higher level of FBG than the wild type. Adjusted
for age, gender, and BMI
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the effect of this sequence variation has not been well stud-
ied, it’s possible to speculate that the betatrophin protein
structure will be affected due to the change in the charge
of the amino acid residue from R to W. A similar R to W
mutation has been previously reported and was shown to
disrupt functional domains within Troponin T or other
proteins [25, 26]. The functional impact of this mutation
on the function of ANGPTL8 requires further investiga-
tion. Our data further highlight the importance of ethnicity
in understanding the role of ANGPTL8 and its sequence
variants in its cellular function. These data combined still
suggest a role for ANGPTL8 in glucose metabolism that
may not involve beta-cell proliferation. It will also require
further functional analysis to better understand this
functional difference and perhaps the cross-talk with
other ethnically specific determinants.
Prospective studies on determining causality and the
involvement of ANGPTL8 in development of T2D is still
lacking and constitutes one of the limitations of the
current study as it represents a cross sectional study.
Another limitation of the current study is the sample
size. Perhaps the lack of statically significant association
between R59W variations and LDL and HDL is caused
by this relatively small sample size. The other factor for
the different trend is the ethnic variation of the current
population where we only studied Arabs. This is due to
the use of Sanger sequencing to sequence the whole
gene instead of looking at a specific SNP. Nonetheless,
one of the main strength of this study is that it high-
lights the importance of the ANGPTL8 gene in a high
risk population that is not very well studied.
Conclusions
In this study we showed that ANGPTL8 R59W gene
variant is associated with higher FBG level in non-
diabetic Arabs compared to the wild type. 59 W showed
a trend toward lower LDL and HDL levels, similar to
African Americans and Hispanic population, however
without being statistically significant. On the other hand,
ANGPTL8 level in plasma was not affected by either
SNP. In conclusion, role of ANGPTL8 in glucose metab-
olism requires further investigation and ethnicity seems
to be a major determinant of the function of ANGPTL8
and better understanding of ethnic differences will be
required to establish the functional role of betatrophin
in multiple ethnicities.
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